Vertex Advances Toward Telaprevir Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.
You may also be interested in...
With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
The race to bring the first oral protease inhibitor to market for the treatment of hepatitis C shows no signs of abating. Merck announced positive data from two Phase III trials evaluating boceprevir Aug. 4, along with plans to initiate a rolling NDA submission and complete the filing by the end of the year. That puts boceprevir on about the same regulatory trajectory as Vertex/Johnson & Johnson's telaprevir, which Vertex has said it will file in the second half of the year
With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
The race to bring the first oral protease inhibitor to market for the treatment of hepatitis C shows no signs of abating. Merck announced positive data from two Phase III trials evaluating boceprevir Aug. 4, along with plans to initiate a rolling NDA submission and complete the filing by the end of the year. That puts boceprevir on about the same regulatory trajectory as Vertex/Johnson & Johnson's telaprevir, which Vertex has said it will file in the second half of the year
With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.